

APCCC Detailed Programme 2019 (subject to minor changes, chairs and speakers to be announced soon)	
Areas of controversy	
<ol style="list-style-type: none"> 1. Locally advanced prostate cancer 2. Biochemical recurrence of prostate cancer after local therapy 3. Management of primary tumour in the metastatic situation 4. Systemic treatment castration-sensitive/naïve prostate cancer 5. Management of non-metastatic castration-resistant prostate cancer 6. Management of metastatic castration-resistant prostate cancer 7. Bone and bone metastases 8. Molecular characterization: Tissue and blood 9. Heterogeneity of men with prostate cancer (ethnicity, elderly) 10. Side effects of hormonal treatments and their management 	
Thursday 29th August 2019	
Time	Session
09:00	Welcome Address Silke Gillessen and Aurelius Omlin on behalf of APCCC
9:15 -10:30 Session 1	State of the art overview on molecular biomarkers and imaging in APC
State of the art on molecular characterization in APC <ul style="list-style-type: none"> - Non-metastatic prostate cancer - Metastatic castration-naïve - Metastatic CRPC 	
Clinical utility of molecular markers	
Discussion	
State of the art on imaging in APC (pitfalls PSMA) <ul style="list-style-type: none"> - Staging High-risk - Staging BCR - Staging + Monitoring castration-naïve - Staging + Monitoring CRPC 	
Discussion (10min)	
COFFEE BREAK	
11:00 – 12:30 Session 2	Node positive prostate cancer (N+ but M0)
How to treat men with newly diagnosed cN+ <ol style="list-style-type: none"> a) by classical imaging b) by novel imaging) cM0 <ul style="list-style-type: none"> • Surgery options (as part of multimodality approach?) • Radiation therapy options (including adjuvant) • Systemic therapy options (Duration of ADT? ADT + Docetaxel, ADT + Abiraterone) • Synthesis – how to best treat cN+ prostate cancer (10min) 	
Discussion	
What to do in men with node positive prostate cancer (cN0 but pN+)?	
Discussion	
12:30 – 13:30 LUNCH	
13:30 – 15:00 Session 3	PSA recurrence after local therapy
Management of men with PSA recurrence after local radiation therapy (including imaging)	

Management of men with PSA recurrence after prostatectomy (including imaging)	
Discussion	
Salvage therapy for local recurrence: Cryotherapy, HIFU, Salvage Brachytherapy	
Oligometastatic recurrence after local therapy – Which patients to treat with local therapy? When to add systemic therapy?	
Discussion	
COFFEE BREAK	
15:30 – 16:30 Session 4	Germline mutations and Somatic mutations
Which man needs genetic counselling and/ or testing?	
Management of men with locally advanced /high risk prostate cancer with germ-line mutations	
Which mutations can guide treatment decisions in the management of men with metastatic prostate cancer	
Discussion	
COFFEE BREAK	
17:00 – 18:15 Session 5	Influence of ethnicity and age in prostate cancer
Ethnicity and prognosis	
Pharmaco-ethnicity and impact on treatment?	
Men ≥80 with APC – oncogeriatric assessment and treatment considerations?	
Report from the consensus conference for developing countries	
Discussion	

Friday 30th August 2019	
Extra session 08:00 – 08:25	Movember Session
Outcomes Research – Ironman project	
Discussion	
08:30 – 10:00 Session 6	Management of metastatic castration-sensitive/naïve prostate cancer
Local treatment of the primary (RT) in the metastatic situation	
Local treatment of the primary (surgery) in the metastatic situation	
Which systemic therapy for which patient with metastatic castration-naïve prostate cancer?	
Addition of Abi vs Docetaxel: Statisticians perspective	
Synthesis Optimal treatment of men with CSPC: a) low volume disease b) high volume disease	
Follow-up on ADT “plus” (including imaging and treatment of oligo-progressive disease)	
Discussion	
COFFEE BREAK	
10:30 – 12:30 Session 7	Management of castration-resistant prostate cancer (CRPC)
Management of men with nmCRPC (including further sequencing, imaging)	
First-line mCRPC after ADT with combination therapy	
Mechanism of resistance to abiraterone or enzalutamide and clinical consequences	
Discussion	
PSMA targeted therapies	
Immunotherapy	
PARP inhibition	
Neuroendocrine spectrum and platinum-based therapy	
Discussion	

12:30 – 13:30 LUNCH	
13:30 – 14:30 Session 8	Side effects of treatment and their management
Integration of PRO in daily practice	
Management of sexuality and incontinence issues in APC	
Management of hot flashes	
Management of metabolic changes	
Management of fatigue, cognition/dementia	
COFFEE BREAK	
15:00 – 16:30 Session 9	Bone and bone metastases
Prevention/Treatment of osteoporosis	
Debate: Antiresorptive therapy in men with bone metastatic CRPC for the reduction of risk of SRE	
<ul style="list-style-type: none"> • For very selected patients only with bone metastases and CRPC • For the majority of men with bone metastases and CRPC • Synthesis: How to best use antiresorptive therapy in CRPC 	
Discussion	
Radium-223 and bone health agents	
The flare phenomenon in bone metastatic APC	
Discussion	
COFFEE BREAK	
17:00 – 18:00 Session 10	The future of advanced prostate cancer management
Wishes from a patients perspective	
In oligometastatic prostate cancer	
In polymetastatic prostate cancer	
In imaging	
In biomarkers	
Discussion	

Saturday 31st of August 2019		
Time	Special Session	Speakers
	All participants will be able to attend the panel meeting as part of the conference.	
08:30 – 10:30	Consensus Panel – Discussion and votes on consensus questions – Part 1	ALL PANEL MEMBERS
COFFEE BREAK		
11:00 – 13:00	Consensus Panel – Discussion and votes on consensus questions – Part 2	ALL PANEL MEMBERS
Closing Remarks: S.Gillessen and A.Omlin		